Breaking News
1. Rouse Avenue Court extends judicial custody of Manish Sisodia and other accused till July 26      2. Supreme Court hearing NEET-UG issue      3. Singer Rahat Fateh Ali Khan arrested in Dubai: Reports      4. Assam CM Himanta Biswa Sarma meets PM Narendra Modi in Delhi      5. India needs to strike balance between import of goods and FDI inflows from China: CEA      6. INDIA bloc to convene meeting tomorrow      7. India's forex reserves surge to record high of $666.85 billion as of July 12      8. Hatred is in the veins of BJP: AAP MP Sanjay Singh      9. Union Home Minister Amit Shah chairs high level meeting with various Heads of Security and Law Enforcement Agencies      10. UP Vidhan Sabha session will begin from July 29      11. Indrani Mukerjea allowed 10-day abroad travel by special CBI court in Mumbai      12. Andhra Pradesh: Union Minister Nitin Gadkari visits Tirumala Venkateshwara Temple in Tirupati      13. Encounter breaks out in J-K's Doda      14. Moderate to heavy rain is expected in Mumbai, its suburbs today      15. Karnataka: Truck and tanker drivers stranded in Akola's Shirur due to landslide      16. Heavy rainfall triggers waterlogging in Mumbai      17. Navdeep Singh farmer activist walks out of jail after getting bail      18. NCB arrests man wanted in Rs 60 crore mephedrone seizure case      19. PM Modi likely to visit BJP headquarters on Thursday, to address party workers: Report      20. Union Cabinet to meet tomorrow, 18th July at 10:30 AM: Report     

Breakthrough Chikungunya Vaccine Approved by USFDA, Offers Vital Protection Against Global Threat

In a significant stride in global healthcare, the US Food and Drug Administration (USFDA) has granted approval to Ixchiq, marking the world's first-ever vaccine designed to prevent chikungunya virus-related diseases. Tailored for individuals aged 18 and above with heightened susceptibility to chikungunya exposure, Ixchiq stands as a crucial response to the escalating threat posed by this virus.

Breakthrough Chikungunya Vaccine Approved by USFDA, Offers Vital Protection Against Global Threat Image Source

Chikungunya, a mosquito-borne virus, has burgeoned into a global health concern, with over 5 million reported cases in the past 15 years. While traditionally associated with tropical regions in Africa, Southeast Asia, and the Americas, its geographical reach has expanded, amplifying the prevalence of the disease worldwide.

Common symptoms of chikungunya encompass fever, joint pain, rash, headache, and muscle pain. In severe cases, the joint pain can persist for months or even years, particularly affecting older adults and those with underlying health conditions.

Dr. Peter Marks, Director of the FDA's Center for Biologics Evaluation and Research, emphasized the vaccine's approval as a crucial step in addressing an unmet medical need and providing a vital tool against a potentially debilitating disease.

Ixchiq, administered as a single muscle injection, contains a weakened form of the live chikungunya virus. Clinical studies in North America involving over 3,500 participants demonstrated the vaccine's safety, with common side effects being headache, fatigue, muscle and joint pain, fever, nausea, and injection site tenderness.

Despite rare severe reactions reported in 1.6% of Ixchiq recipients, the benefits of the vaccine outweigh the potential risks. The FDA mandates a postmarketing study to further assess these risks.

Transmission of the chikungunya virus to newborns has been documented, making Ixchiq's approval a significant development in safeguarding vulnerable populations. While the vaccine virus was detected in the blood shortly after vaccination, its impact on pregnant individuals and newborns remains uncertain.

Also Read: Tragic Loss In The Music World: South Korean Singer Nahee's Sudden Demise Stuns The Music Community

Ixchiq's approval comes under the Accelerated Approval pathway, reflecting the urgency in addressing the serious and life-threatening nature of chikungunya. Fast Track and Breakthrough Therapy designations, along with Priority Review, underscore the vaccine's significance in combating this global health menace.

Valneva Austria GmbH, the manufacturer, received a tropical disease priority review voucher as an incentive for advancing medical solutions targeting certain tropical diseases. This monumental approval represents a paradigm shift in combating chikungunya, offering hope and protection on a global scale. 

No Image

You May Also Like